Exelixis to slash 160 jobs as prostate cancer trial fails

Once high-flying Exelixis Inc. will cut about 160 jobs after disclosing that its drug Cometriq failed a late-stage trial against a type of prostate cancer...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.